Aesica to Expand HPAPI Capacity at Two Sites in U.K.

Aesica Pharmaceuticals (Newcastle upon Tyne, U.K.), a provider of active pharma ingredients (API), formulations, and custom synthesis, says it plans to upgrade its API manufacturing facilities, enabling it to manufacture high potency APIs (HPAPIs) at commercial scale. The expansion will be carried out at Aesica’s facilities at Cramlington and Queenborough in the U.K., the company tells CW. The new HPAPI investment "will be staggered and will amount to about $6.6 million over the next three years. HPAPI capabilities are a definite priority for us at...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers